---
title: "Nanjing Leads Biolabs Wins HKEX Approval for H-Share Full Circulation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286430077.md"
description: "Nanjing Leads Biolabs Co., Ltd. has received approval from the Hong Kong Stock Exchange for the listing of 44,391,598 converted H shares under its H Share Full Circulation program. This conversion involves 23 shareholders and aims to enhance liquidity and marketability of the company's equity. The move is expected to broaden the investor base and strengthen its position in the biotech sector. The latest analyst rating for the stock (HK:9887) is a Buy with a price target of HK$100.50."
datetime: "2026-05-14T13:51:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286430077.md)
  - [en](https://longbridge.com/en/news/286430077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286430077.md)
---

# Nanjing Leads Biolabs Wins HKEX Approval for H-Share Full Circulation

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has shared an update.

Nanjing Leads Biolabs Co., Ltd. has received approval from the Hong Kong Stock Exchange for the listing and trading of 44,391,598 converted H shares under its H Share Full Circulation program. The conversion involves 23 participating shareholders whose previously unlisted shares will become tradable H shares, slightly reshaping the firm’s shareholder structure.

The move is designed to enhance liquidity and marketability of the company’s equity by allowing these converted shares to circulate freely in Hong Kong. This step is expected to broaden the company’s investor base, improve capital market access, and potentially strengthen its position in the biotech sector by aligning shareholder interests with an actively traded H-share float.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$100.50 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

**More about Nanjing Leads Biolabs Co., Ltd. Class H**

Nanjing Leads Biolabs Co., Ltd. is a biotechnology company headquartered in the People’s Republic of China and listed in Hong Kong as an H-share issuer. The company operates in the biopharmaceutical sector, focusing on the research, development, and commercialization of innovative medical and life science products for domestic and international markets.

**Average Trading Volume:** 921,812

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$15B

### Related Stocks

- [09887.HK](https://longbridge.com/en/quote/09887.HK.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [Fingerprint Cards AB Bets on Merger-Led Turnaround](https://longbridge.com/en/news/286333864.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)